Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
- 31 March 2004
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 5 (3), 221-230
- https://doi.org/10.1016/s1535-6108(04)00050-9
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasiasSeminars in Oncology, 2003
- Nocodazole-induced p53-dependent c-Jun N-terminal Kinase Activation Reduces Apoptosis in Human Colon Carcinoma HCT116 CellsOnline Journal of Public Health Informatics, 2002
- Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancerExpert Opinion on Investigational Drugs, 2002
- Interleukin-6 Is an Autocrine Growth Factor in Human Prostate CancerThe American Journal of Pathology, 2001
- Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancerExpert Opinion on Investigational Drugs, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001
- Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) CellsOnline Journal of Public Health Informatics, 2001
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- The Insulin-Like Growth Factor-I Receptor Signaling Pathways Are Important for Tumorigenesis and Inhibition of ApoptosisCritical Reviews™ in Oncogenesis, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958